Company intelligence / Profile preview
VRG Therapeutics
Budapest, Budapest, Hungaryvrgtherapeutics.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Successfully extended the half-life of its Kv1.3-targeting lead molecule, enabling once-monthly dosing for patients with atopic dermatitis, maintaining best-in-class affinity and selectivity as demonstrated by in vivo pharmacokinetics studies[3]
- Therapeutic areas
- OncologyDermatologyImmunologyNeurology
- Modalities
- Miniproteinstherapeutic peptidesproteins
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →03
Partnerships
Collaboration to utilize Komondor (High Performance Computing infrastructure)[6]
Beyond the preview
Go deeper on VRG Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VRG Therapeutics.